Q-omics provides the consensus-scored MSTN profile across patient tissues and cancer cell-line models. MSTN expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MSTN is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MSTN RNA expression shows 17,684 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KICH, and UVM as cancer lineages where MSTN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSTN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSTN survival associations across molecular data types. MSTN RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSTN RNA expression–survival associations across cancer types. High MSTN expression shows unfavorable associations in UVM, but favorable associations in BLCA, HNSC, MESO, READ and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MSTN RNA expression.
This table summarizes MSTN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MSTN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSTN shows lower tumor expression in KICH, COAD, STAD, HNSC, BLCA and UCEC. The KICH box plot shows higher MSTN RNA expression in normal versus tumor tissue (log2 FC = −0.482, t-test p < 0.001).
This table shows molecular features associated with MSTN in patient tissues and cancer cell lines. In patient samples, MSTN shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MSTN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
